The US Food and Drug Administration (FDA) has granted 510(k) approval for Iridex’s Cyclo G6 Laser System, to treat patients with multiple stages of glaucoma.
Featuring firm’s MicroPulse tissue-sparing technology, the Cyclo G6 laser system has been developed to treat patients diagnosed with a wide range of glaucoma disease states.
Iridex president and CEO William Moore said: ""The Cyclo G6 system extends the reach of Iridex’s proprietary MicroPulse technology to a broader group of ophthalmologists who are seeking better alternatives for treating glaucoma than drug regimens or invasive surgical procedures.
"That added reach, combined with the recurring use of specialty probes associated with the Cyclo G6, is expected to help drive growth in an important recurring revenue component of our business."
Initially, the laser system will be marketed with two disposable delivery probes, including MicroPulse P3 probe and the G-Probe.
In addition, the company is planning to introduce new probes in the coming year, in a bid to enhance range of application in glaucoma treatment.
Established in 1989, Iridex develops and markets laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market.